Clinical Trial Update: BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating BCMA CAR-T cell therapy in high-risk newly diagnosed multiple myeloma patients who remain MRD-positive after first-line auto…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BCMA CAR-T Cell Therapy

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Multiple Myeloma | Phase 2 | Status: RECRUITING